ANDA 83149, held by Novartis Pharmaceuticals. Tripelennamine Hydrochloride.
As of Nov 21, 2026, ANDA 83149 (Pbz), held by Novartis Pharmaceuticals, was first approved by FDA on Sep 6, 1973, with 10 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 6, 1973 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Pbz25MG · tablet;oral | Tripelennamine Hydrochloride | Discontinued |
| Jul 20, 1999 | Supplement 20Manufacturing | Approved | None posted |
| Oct 30, 1997 | Supplement 17Manufacturing | Approved | None posted |
| Aug 6, 1997 | Supplement 19Manufacturing | Approved | None posted |
| Mar 26, 1997 | Supplement 18Manufacturing | Approved | None posted |
| Aug 3, 1995 | Supplement 16Manufacturing | Approved | None posted |
| Apr 16, 1985 | Supplement 15Manufacturing | Approved | None posted |
| Apr 16, 1985 | Supplement 14Manufacturing | Approved | None posted |
| Oct 12, 1983 | Supplement 13Manufacturing | Approved | None posted |
| Oct 12, 1983 | Supplement 12Manufacturing | Approved | None posted |
| Oct 12, 1983 | Supplement 10Manufacturing | Approved | None posted |
| Sep 6, 1973 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters